Joseph K Agyin

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. pmc BU-32: a novel proteasome inhibitor for breast cancer
    Joseph K Agyin
    Department of Biochemistry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Breast Cancer Res 11:R74. 2009
  2. pmc Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma
    Joseph K Agyin
    University of Texas Health Science Center at San Antonio, Biochemistry Department, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States University of Texas Health Science Center at San Antonio, Cellular and Structural Biology Department, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States Electronic address
    Bioorg Med Chem Lett 23:6455-8. 2013
  3. pmc Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells
    Dimple Chakravarty
    Department of Obstetrics and Gynecology and CTRC at The UT Health Science Center, San Antonio, Texas 78229 3900, USA
    Cancer Res 70:4092-101. 2010
  4. ncbi request reprint Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor
    Abhik Bandyopadhyay
    Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Cancer Res 66:6714-21. 2006
  5. pmc Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells
    Sudipa S Roy
    Department of Biochemistry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA
    Cancer Chemother Pharmacol 73:1263-71. 2014
  6. pmc Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor
    Erik V Verona
    Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Protein Eng Des Sel 21:463-73. 2008

Research Grants

  1. Bone-seeking proteasome inhibitors for myeloma
    Joseph Agyin; Fiscal Year: 2007

Collaborators

Detail Information

Publications6

  1. pmc BU-32: a novel proteasome inhibitor for breast cancer
    Joseph K Agyin
    Department of Biochemistry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Breast Cancer Res 11:R74. 2009
    ..This underscores the need to find new and more efficacious proteasome inhibitors. In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499-S) using in vitro and in vivo breast cancer models...
  2. pmc Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma
    Joseph K Agyin
    University of Texas Health Science Center at San Antonio, Biochemistry Department, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States University of Texas Health Science Center at San Antonio, Cellular and Structural Biology Department, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States Electronic address
    Bioorg Med Chem Lett 23:6455-8. 2013
    ..The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner. ..
  3. pmc Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells
    Dimple Chakravarty
    Department of Obstetrics and Gynecology and CTRC at The UT Health Science Center, San Antonio, Texas 78229 3900, USA
    Cancer Res 70:4092-101. 2010
    ....
  4. ncbi request reprint Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor
    Abhik Bandyopadhyay
    Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Cancer Res 66:6714-21. 2006
    ....
  5. pmc Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells
    Sudipa S Roy
    Department of Biochemistry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA
    Cancer Chemother Pharmacol 73:1263-71. 2014
    ..Our results suggest that BU-32 might be a potential chemotherapeutic agent with promising antitumor activity for the treatment of MM...
  6. pmc Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor
    Erik V Verona
    Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Protein Eng Des Sel 21:463-73. 2008
    ..Thus, BG(E)RII is a potent pan-TGFbeta inhibitor in vitro and has potential for blocking TGFbeta-induced pathogenesis in vivo...

Research Grants2

  1. Bone-seeking proteasome inhibitors for myeloma
    Joseph Agyin; Fiscal Year: 2007
    ..These studies will serve to identify the most promising candidate prodrug to be subsequently tested in clinical trials as a novel treatment modality for MM. ..